Skip to main content
. Author manuscript; available in PMC: 2019 Apr 22.
Published in final edited form as: Alzheimers Dement. 2018 Nov 9;15(3):487–496. doi: 10.1016/j.jalz.2018.09.010

Figure 3. CSF Mid-region and N-terminal-containing fragments of tau, but not full-length tau are elevated in AD and AD-MCI.

Figure 3

Tau was measured in the CSF of subjects from the Discovery Cohort using three distinct ELISAs for (A) mid-region tau (BT2-Tau5), (B) NT1 tau (Tau12-BT2), and (C) NT2 tau (Tau12-ADx202), and two Simoa-based assays for (D) FL tau (TauAB-Tau12) and (E) NT1 tau (BT2-Tau12). Healthy control subjects were from the HABS study (NC HABS) and UCL study (NC UCL). Each point represents a single individual and means ± SEM are indicated. Differences between groups were assessed with Kruskal-Wallis H test followed by Dunn’s post-hoc test. All assays, except the FL assay detected higher levels of tau in AD-MCI and AD, than NC. n.s., non-significant; p>0.05; *p<0.05; ***p<0.001.